publication date: Jul. 1, 2016

NCI CTEP-Approved Trials for the Month of June

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Pilot Phase

9913: A Pilot Study of Neoadjuvant Nivolumab in High-Risk, Non-Metastatic, Renal Cell Carcinoma. Memorial Sloan Kettering Cancer Center; Voss, Martin Henner. (646) 422-4479

 

Phase I

9892: Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer. University of Pittsburgh Cancer Institute LAO; Taylor, Sarah E. (412) 641-4455

9938: Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors. University of Pittsburgh Cancer Institute LAO; Villaruz, Liza C. (412) 648-6577

AMC-097: A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells. AIDS Malignancy Consortium; Abedi, Mehrdad. (916) 734-3771

 

Phase I/II

NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. NRG Oncology; Burger, Robert Allen. (215) 662-3318

 

Phase II

EA1141: Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts. ECOG-ACRIN Cancer Research … Continue reading CCL June 2016 – NCI CTEP-Approved Trials For the Month of June

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.